Oppenheimer Cuts NuCana (NASDAQ:NCNA) Price Target to $25.00

NuCana (NASDAQ:NCNA) had its price target cut by Oppenheimer from $150.00 to $25.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the stock.

Separately, William Blair downgraded NuCana from an outperform rating to a market perform rating in a research report on Friday, August 30th.

NuCana Trading Down 10.5 %

NASDAQ:NCNA opened at $2.73 on Tuesday. The company has a market capitalization of $7.22 million, a P/E ratio of -0.23 and a beta of 1.01. NuCana has a 12 month low of $2.53 and a 12 month high of $20.25. The business’s 50-day moving average is $4.09 and its 200 day moving average is $4.89.

Institutional Investors Weigh In On NuCana

A hedge fund recently bought a new stake in NuCana stock. Baillie Gifford & Co. bought a new stake in shares of NuCana plc (NASDAQ:NCNA) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 146,360 shares of the company’s stock, valued at approximately $378,000. Baillie Gifford & Co. owned about 5.54% of NuCana as of its most recent filing with the Securities & Exchange Commission. 44.00% of the stock is owned by hedge funds and other institutional investors.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.